Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis
GSK1004723; GSK835726
HHI112864
NCT00972504
Rhinitis, Allergic, Seasonal
Phase 2
 
August 2015

Powered by ideaPoint, Inc.